Aspergillus fumigatus harbouring the sole Y121F mutation shows decreased susceptibility to voriconazole but maintained susceptibility to itraconazole and posaconazole

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 12, 2014, Pages 3244-3247

  Lescar, J ^a,b   Meyer, I ^c   Akshita, K ^a   Srinivasaraghavan, K ^d   Verma, C ^a,d,e   Palous, M ^c   Mazier, D ^b,c,f   Datry, A ^b,c,f   Fekkar, A ^b,c,f  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b Assistance publique Hôpitaux de Paris   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d BIOINFORMATICS INSTITUTE   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f SORBONNE UNIVERSITÉ   (France)

Author keywords

Antifungal resistance; Azole drugs; Cyp51A; Ergosterol

Indexed keywords

ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; CYTOCHROME P-450 CYP51A, ASPERGILLUS; CYTOCHROME P450; FUNGAL DNA; FUNGAL PROTEIN; TRIAZOLE DERIVATIVE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; CYP51A GENE; FUNGAL STRAIN; FUNGUS ISOLATION; GENE; GENE MUTATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DYNAMICS; MOLECULAR MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; WILD TYPE; CHEMISTRY; DNA SEQUENCE; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; MISSENSE MUTATION; MOLECULAR GENETICS;

ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; CYTOCHROME P-450 ENZYME SYSTEM; DNA, FUNGAL; DRUG RESISTANCE, FUNGAL; FUNGAL PROTEINS; ITRACONAZOLE; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; SEQUENCE ANALYSIS, DNA; TRIAZOLES; VORICONAZOLE;

EID: 84934311736     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku316     Document Type: Article

References (21)

1. Chowdhary A, Kathuria S, Xu J et al. Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog 2013; 9: e1003633.
2. Vermeulen E, Lagrou K, Verweij PE. Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis 2013; 26: 493-500.
3. Bueid A, Howard SJ, Moore CB et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother 2010; 65: 2116-8.
4. Snelders E, Huis In't Veld RA, Rijs AJ et al. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol 2009; 75: 4053-7.
5. VanderLinden JW,Camps SM,KampingaGAet al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis 2013; 57: 513-20.
6. Vermeulen E, Maertens J, Schoemans H et al. Azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation emerging in Belgium, July 2012. Euro Surveill 2012; 17: pii=20326.
7. Chowdhary A, Sharma C, Kathuria S et al. Azole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India. J Antimicrob Chemother 2014; 69: 555-7.
8. Fischer J, van Koningsbruggen-Rietschel S, Rietschel E et al. Prevalence and molecular characterization of azole resistance in Aspergillus spp. isolates from German cystic fibrosis patients. J Antimicrob Chemother 2014; 69: 1533-6.
9. Morio F, Aubin GG, Danner-Boucher I et al. High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis. J Antimicrob Chemother 2012; 67: 1870-3.
10. Alanio A, Sitterle E, Liance M et al. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother 2011; 66: 371-4.
11. Snelders E, Karawajczyk A, Schaftenaar G et al. Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob Agents Chemother 2010; 54: 2425-30.
12. Ntie-Kang F, Kannan S, Wichapong K et al. Binding of pyrazole-based inhibitors to Mycobacterium tuberculosis pantothenate synthetase: docking and MM-GB(PB)SA analysis. Mol Biosyst 2014; 10: 223-39.
13. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996; 14: 33-8, 27-8.
14. Arendrup MC, Mavridou E, Mortensen KL et al. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One 2010; 5: e10080.
15. Denning DW, Radford SA, Oakley KL et al. Correlation between in vitro susceptibility testing to itraconazole and in vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997; 40: 401-14.
16. Howard SJ, Cerar D, Anderson MJ et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15: 1068-76.
17. Verweij PE, Mellado E, MelchersWJ. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007; 356: 1481-3.
18. Fraczek MG, Bromley M, Bowyer P. An improved model of the Aspergillus fumigatus CYP51A protein. Antimicrob Agents Chemother 2011; 55: 2483-6.
19. Chen CK, Leung SS, Guilbert C et al. Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole. PLoS Negl Trop Dis 2010; 4: e651.
20. Mast N, Charvet C, Pikuleva IA et al. Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain. J Biol Chem 2010; 285: 31783-95.
21. Monk BC, Tomasiak TM, Keniya MV et al. Architecture of a single membrane spanning cytochrome P450 suggests constraints that orient the catalytic domain relative to a bilayer. Proc Natl Acad Sci USA 2014; 111: 3865-70.